Status:
COMPLETED
Cilostazol Verse Asprin for Vascular Dementia in Poststroke Patients With White Matter Lesions
Lead Sponsor:
Peking University First Hospital
Collaborating Sponsors:
Zhejiang Otsuka Pharmaceutical Co., Ltd.
Conditions:
Vascular Dementia
Stroke
Eligibility:
All Genders
40-80 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to evaluate the efficacy of PDE-3 inhibitor, cilostazol, in prevention and treatment of vascular dementia, in those with brain white matter lesions and vascular risk facto...
Eligibility Criteria
Inclusion
- Age ranging from 40 to 80 years
- After newly ischemic stroke from 3 months to 2 years
- Brain CT or MRI shows stroke lesions and white matter lesions, ARWMC(Age Related White Matter Change)\>=4
- Moderate or mild cognitive deficits: MMSE 12-26
- Vascular or mixed dementia: Hachinski ischemic score\>4
- Moderate or mild disability: MRS\<=4,NIHSS\<20
- Informed consent
Exclusion
- Definitive diagnosis of dementia prior to the stroke
- Cerebral hemorrhage in the past
- Cerebral embolism result from cardiogenic embolus
- Critically ills: MRS\>4,NIHSS\>=20
- Bed-ridden patient who is hardly discovered newly stroke
- patient with sever cardiac, hepatic or nephric complication
- dementia caused not by vascular lesions
- other diseases disturb the cognitive evaluation
- susceptibility to varieties of allergen
- abstain from Cilostazol or Asprin
- antiplatelet treatment, anticoagulation or fibrinolysis are needed because of other diseases
- rejected to participate by the patient or the family
Key Trial Info
Start Date :
March 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2011
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT00847860
Start Date
March 1 2008
End Date
June 1 2011
Last Update
May 6 2015
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University First Hospital
Beijing, Beijing Municipality, China, 100034
2
Shanghai Hua Shan Hospital
Shanghai, Shanghai Municipality, China, 200040